---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065314"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:58:30.834370+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# XOMA reports FY 2022 net loss of $17.1M; Vabysmo commercial payments begin

## Summary
- FY 2022 revenue $6.0M vs $38.2M in 2021; net loss $17.1M vs net income $15.8M.
- Cash $57.8M at Dec 31, 2022; no debt.
- Received second Vabysmo commercial payment from Roche in Feb 2023; 0.5% interest in sales.
- Ebopiprant deal with Organon offers up to $378M milestones plus mid-single/low-teen royalties.
- Executive Chairman Owen Hughes and CIO Brad Sitko added to lead royalty acquisition strategy.

## SEC filing metadata
- accession: 0001193125-23-065314
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/0001193125-23-065314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/d479992d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065314
- JSON: https://secwatch.observer/filing/0001193125-23-065314.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065314.txt

## Key facts
- Earnings Releases
  XOMA Royalty Corp reported the quarter and year ended December 31, 2022 results: revenue $1.5 million and $6.0 million, net income Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: $1.5 million and $6.0 million
  - Net income: Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million
  - Result: reported results
  source text: said Brad Sitko, Chief Investment Officer of XOMA. Fourth Quarter and Full Year 2022 Financial Results Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively. For the full year of 2022, XOMA’s reported revenues were related to milestone payments of $2.0 million from Rezolute, $0.8 million from Takeda,
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/0001193125-23-065314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.